Skip to main content
. Author manuscript; available in PMC: 2019 Apr 8.
Published in final edited form as: Int J Cancer. 2014 Sep 1;136(7):1600–1607. doi: 10.1002/ijc.29136

Table 3. Basecase screening policy compared with stopping screening 2012.

Lifetime Risk % 50-74, 1y, PSAt=3 Stop Screening 2012
Prostate Cancer Mortality 2.4 2.8
Metastasis 0.7 1.7
Overdiagnosis 3.8 0
Detection 14.0 9.7
Performance
PCM Benefit % 19.4 -
Number Needed to Screen 162 -
Number Needed to Treat 15 -
Overdiagnosis (% of Screen Detected) 43.8 -
Metastasis (% of Detected) 4.7 17.8
*

In the absence of screening (also prior to 2012) the lifetime risk of PCM is 3.0%.

#

PSAt stands for prostate-specific antigen threshold for biopsy referral.